We have located links that may give you full text access.
Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages of Mycobacterium tuberculosis infection.
Journal of Infection 2018 December 6
OBJECTIVE: We aimed to identify plasma cytokine biomarkers that differentiate the infection stages of Mycobacterium tuberculosis (MTB).
METHODS: This study included a total of 227 subjects consisting of active tuberculosis (ATB) patients, latent tuberculosis infection (LTBI) individuals, and healthy controls (HC). We analyzed the expressions of 38 plasma cytokines in the discovery cohort to identify the biosignatures for differentiating MTB infection states, area under the curve (AUC) were used to evaluate the diagnostic efficiency. The AUC of unique plasma biomarker was confirmed in the validation cohort.
RESULTS: In the discovery cohort, the AUC of the 8-marker biosignature (eotaxin, MIP-1α, MDC, IP-10, MCP-1, IL-1α, IL-10, and TNF-α) in diagnosing ATB was 1.0. The sensitivity and specificity of the 5-marker biosignature (IP-10, MCP-1, IL-1α, IL-10, and TNF-α) in diagnosing LTBI were 94% and 81.25%, respectively. The AUC of the 3-signature biosignature (eotaxin, MDC, MCP-1) in differentiating ATB from LTBI was 0.94, with the sensitivity and specificity of 87.76% and 91.84%, respectively. Moreover, among all the single cytokine biomarkers, MCP-1 exhibited the highest AUC in diagnosing ATB (0.98) and differentiating ATB from LTBI (0.91). In the subsequent validation cohort analysis, we identified that the AUC of MCP-1 in diagnosing ATB and differentiating ATB from LTBI were 0.97 and 0.89, respectively, which was generally consistent with the results of the discovery cohort.
CONCLUSION: Cytokine levels in plasma can be used as biosignatures to diagnose ATB. The cytokine concentrations vary during the different stages of MTB infection, which might serve as biomarkers in differentiating ATB from LTBI. Future studies with a larger population and data from multiple institutions are needed to validate our findings.
METHODS: This study included a total of 227 subjects consisting of active tuberculosis (ATB) patients, latent tuberculosis infection (LTBI) individuals, and healthy controls (HC). We analyzed the expressions of 38 plasma cytokines in the discovery cohort to identify the biosignatures for differentiating MTB infection states, area under the curve (AUC) were used to evaluate the diagnostic efficiency. The AUC of unique plasma biomarker was confirmed in the validation cohort.
RESULTS: In the discovery cohort, the AUC of the 8-marker biosignature (eotaxin, MIP-1α, MDC, IP-10, MCP-1, IL-1α, IL-10, and TNF-α) in diagnosing ATB was 1.0. The sensitivity and specificity of the 5-marker biosignature (IP-10, MCP-1, IL-1α, IL-10, and TNF-α) in diagnosing LTBI were 94% and 81.25%, respectively. The AUC of the 3-signature biosignature (eotaxin, MDC, MCP-1) in differentiating ATB from LTBI was 0.94, with the sensitivity and specificity of 87.76% and 91.84%, respectively. Moreover, among all the single cytokine biomarkers, MCP-1 exhibited the highest AUC in diagnosing ATB (0.98) and differentiating ATB from LTBI (0.91). In the subsequent validation cohort analysis, we identified that the AUC of MCP-1 in diagnosing ATB and differentiating ATB from LTBI were 0.97 and 0.89, respectively, which was generally consistent with the results of the discovery cohort.
CONCLUSION: Cytokine levels in plasma can be used as biosignatures to diagnose ATB. The cytokine concentrations vary during the different stages of MTB infection, which might serve as biomarkers in differentiating ATB from LTBI. Future studies with a larger population and data from multiple institutions are needed to validate our findings.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app